peridinyl, piperazinyl, homopiperazinyl and morpholinyl being optionally substituted by C_1–C_6 alkyl or C_3–C_7 cycloalkyl;

each R^6 is independently either H, C_1–C_6 alkyl or C_3–C_7 cycloalkyl;

R^7 is C_1–C_6 alkyl or C_3–C_7 cycloalkyl;

R^8 is a five or six-membered, aromatic heterocyclic group containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom or (iii) 1 or 2 oxygen or sulphur heteroatom(s), said heterocyclic group being optionally substituted by halo, oxo, —CN, —COR^5, —$CONR^5R^5$, —$SO_2NR^5R^5$, —$NR^5SO_2R^5$, —OR^5, —NR^5R^5, —(C_1–C_6 alkylene)—NR^5R^5, C_1–C_6 alkyl, fluoro(C_1–C_6)alkyl or C_3–C_7 cycloalkyl;

R^9 is a four to seven-membered, saturated or partially unsaturated heterocyclic group containing (i) 1 or 2 nitrogen heteroatom(s) or (ii) 1 nitrogen heteroatom and 1 oxygen or 1 sulphur heteroatom or (iii) 1 oxygen or sulphur heteroatom, said heterocyclic group being optionally substituted by oxo, C_1–C_6 alkyl, C_3–C_7 cycloalkyl, —SO_2R^5, —$CONR^5R^5$, —$COOR^5$, —CO—(C_1–C_6 alkylene)—OR^5 or —COR^5 and optionally substituted on a carbon atom which is not adjacent to a heteroatom by halo, —OR^5, —NR^5R^5, —NR^5COR^5, —NR^5COOR^5, —$NR^5CONR^5R^5$, —$NR^5SO_2R^5$ or —CN;

R^{10} is C_1–C_6 alkyl substituted by R^8, R^9, —$CONR^5R^5$, —NR^5COR^5 or —NR^5R^5;

R^{11} is phenyl optionally substituted by halo, —CN, —COR^5, —$CONR^5R^5$, —$SO_2NR^5R^5$, —$NR^5SO_2R^5$, —OR^5, —NR^5R^5, —(C_1–C_6 alkylene)—NR^5R^5, C_1–C_6 alkyl, halo(C_1–C_6)alkyl or C_3–C_7 cycloalkyl; and

x and n are independently 0, 1 or 2.

2. A pharmaceutical composition comprising a compound according to claim **1** and one or more pharmaceutically acceptable excipients, diluents or carriers.

3. A pharmaceutical composition according to claim **2** comprising one or more additional therapeutic agents.

* * * * *